Partnering

Ground Fluor Pharmaceuticals, Inc., (GFP) is the exclusive worldwide licensee to a breakthrough iodonium chemistry for the rapid, carrier-free, high-yielding synthesis of F18-Positron Emission Tomography (PET) imaging agents.  SWIFT™ technology allows Swift Fluorine Tagging of small molecules.  The technology was developed by Dr. Stephen DiMagno at the University of Nebraska- Lincoln.  Technology licensees can now rapidly produce finished, highly potent (no-carrier-added) pharmaceutical F18 PET agents in very high yields using conventional modular synthesizers available in the industry.  No heavy metals are used in the synthetic processes, and purification of final product can generally be performed using single phase extraction (SPE) without the need for high pressure liquid chromatography (HPLC).

The Company is partnering with third-parties to provide research and development assistance in the development of F18 labeling of their proprietary agents.

Licenses to the use of the technology for specific applications are available from Ground Fluor Pharmaceuticals, Inc.

For further information, please contact Dr. Stephen DiMagno at 402-875-0055 |  stephendimagno@gfpharma.com or Dr. Allan Green at 617-447-5999 | amgreen@gfpharma.com.